Current state of oncologic 18F-FDG PET/CT in Japan: A nationwide survey

Document Type : Short communication


1 Department of Radiology, Toyohashi Municipal Hospital, Toyohashi, Japan

2 Department of Quantum Medical Technology, Institute of Medical, Pharmaceutical and Health Sciences,Kanazawa University, Kanazawa, Japan

3 Department of Radiological Sciences, School of Health Sciences, International University of Health and Welfare,Tochigi, Japan

4 Department of Physics, Kanazawa Medical University, Kanazawa, Japan

5 Department of Radiological Technology, Kurashiki Central Hospital, Kurashiki, Japan

6 Department of Radiological Sciences, Ibaraki prefectural University of Health Sciences, Ibaraki, Japan


Objectives: Combined positron emission tomography/computed tomography (PET/CT) has gradually advanced with the introduction of newly developed techniques. However, the recent status of imaging techniques (e.g., scanning range, availability of correction methods, and decisions on performing delayed scan) in oncologic PET/CT with 18F-fluorodeoxyglucose (18F-FDG) in Japan is unclear. We conducted a nationwide cross-sectional survey to document 18F-FDG PET/CT protocols and clarify the recent status of imaging techniques for oncologic 18F-FDG PET/CT in Japan.
Methods: We conducted a web survey hosted by the Japanese Society of Radiological Technology between October and December 2017. The questionnaire included nine items on the demographics of the respondents, their scan protocols, and additional imaging to their routine protocols.
Results: We received responses from 119 Japanese technologists who performed 18F-FDG PET/CT in practice. Almost all the respondents stated that the scanning range was from the top of the head to the pelvis or mid-thigh region. Newly developed techniques were used by fewer than half of the respondents. Most respondents performed additional imaging in consultation with physicians, such as delayed imaging (83%) or an extended scanning range for early imaging (55%).
Conclusions: Our survey helps in clarifying the recent state of oncologic 18F-FDG PET/CT imaging techniques in Japan. Given that 18F-FDG PET/CT practices most frequently performed additional imaging along with their routine scan protocol, the practice constitutes the most varied examination performed in Japanese nuclear medicine.


1. The Present State of Nuclear Medicine Practice in Japan—A Report of the 8th Nationwide Survey in 2017. Radioisotopes. 2018; 67(7):339-87.
2. Armstrong IS, Kelly MD, Williams HA, Matthews JC. Impact of point spread function modelling and time of flight on FDG uptake measurements in lung lesions using alternative filtering strategies. EJNMMI physics. 2014; 1(1): 99.
3. Hirata K, Hattori N, Takeuchi W, Shiga T, Morimoto Y, Umegaki K, et al. Metabolic Activity of Red Nucleus and Its Correlation with Cerebral Cortex and Cerebellum: A Study Using a High-Resolution Semi-conductor PET System. J Nucl Med. 2015; 56 (8):1206-11.
4. Nishiyama Y, Kinuya S, Kato T, Kayano D, Sato S, Tashiro M, et al. Nuclear medicine practice in Japan: a report of the eighth nationwide survey in 2017. Ann Nucl Med. 2019; 33(10):725-32.
5. Karp JS, Surti S, Daube-Witherspoon ME, Muehllehner G. Benefit of time-of-flight in PET: experimental and clinical results. J Nucl Med. 2008; 49(3):462-70.
6. Akamatsu G, Ishikawa K, Mitsumoto K, Taniguchi T, Ohya N, Baba S, et al. Improvement in PET/CT image quality with a combination of point-spread function and time-of-flight in relation to reconstruction parameters. J Nucl Med. 2012; 53(11):1716-22.
7. PET I. CT atlas on quality control and image artifacts IAEA human health series No 27. Vienna, Austria: International Atomic Energy Agency. 2014.
8. Crivellaro C, De Ponti E, Elisei F, Morzenti S, Picchio M, Bettinardi V, et al. Added diagnostic value of respiratory-gated 4D 18F-FDG PET/CT in the detection of liver lesions: a multicenter study. Eur J Nucl Med Mol Imaging. 2018; 45(1):102-9.
9. Delbeke D, Re C, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0 J Nucl Med.2006 May;47(5):885-95.
10. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015; 42(2):328-54.
11. Graham MM, Badawi RD, Wahl RL. Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med. 2011; 52(2):311-7.
12. Beyer T, Czernin J, Freudenberg LS. Variations in clinical PET/CT operations: results of an international survey of active PET/CT users. J Nucl Med. 2011; 52(2):303-10.
13. Minamimoto R, Senda M, Uno K, Jinnouchi S, Iinuma T, Ito K, et al. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey.Ann Nucl Med. 2007; 21(9):481-98.
14. Osman MM, Chaar BT, Muzaffar R, Oliver D, Reimers HJ, Walz B, et al. 18F-FDG PET/CT of patients with cancer: comparison of whole-body and limited whole-body technique. AJR Am J Roentgenol. 2010; 195(6):1397-403.
15. Ishimori T, Pv P, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med.2005; 46(5):752-7.
16. Tan JC, Chatterton BE. Is there an added clinical value of "true"whole body (18) F-FDG PET/CT imaging in patients with malignant melanoma? Hell J Nucl Med.2012; 15(3):202-5.
17. Kato T, Ichikawa H, Miwa K, Okuda K, Shibutani T, Nagaki A, et al. A Nationwide Survey on Additional Scan in Nuclear Medicine Imaging. Nihon Hoshasen Gijutsu Gakkai zasshi. 2020; 76(3):285-94.
18. Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. European Journal of Nuclear Medicine. 1999; 26(10):1345-8.
19. Lee JW, Kim SK, Lee SM, Moon SH, Kim TS. Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer. Mol Imaging Biol. 2011; 13(3):565-72.
20. Fuster D, Lafuente S, Setoain X, Navales I, Perissinotti A, Pavia J, et al. Dual-time point images of the liver with (18) F-FDG PET/CT in suspected recurrence from colorectal cancer. Rev Esp Med Nucl Imagen Mol. 2012; 31(3):111-6.
21. Arena V, Skanjeti A, Casoni R, Douroukas A, Pelosi E. Dual-phase FDG-PET: delayed acquisition improves hepatic detectability of pathological uptake. Radiol Med. 2008; 113(6):875-86.
22. Park S, Paeng JC, Kang CH, Cheon GJ, Kang KW, Chung JK, et al. Dual-time point (18) F-FDG PET/CT for the staging of oesophageal cancer: the best diagnostic performance by retention index for N-staging in non-calcified lymph nodes. Eur J Nucl Med Mol Imaging. 2018; 45(8):1317-28.
23. Hu Q, Wang W, Zhong X, Yuan S, Fu Z, Guo H, et al. Dual-time-point FDG PET for the evaluation of locoregional lymph nodes in thoracic esophageal squamous cell cancer. Eur J Radiol. 2009; 70(2):320-4.
24. Demura Y, Tsuchida T, Ishizaki T, Mizuno S, Totani Y, Ameshima S, et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med. 2003; 44(4):540-8.
25. Uesaka D, Demura Y, Ishizaki T, Ameshima S, Miyamori I, Sasaki M, et al. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer. J Nucl Med. 2008; 49(10):1606-12.
26. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al. Delayed 18F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer. 2000; 89(12):2547-54.
27. Cheng G, Torigian DA, Zhuang H, Alavi A. When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? Eur J Nucl Med Mol Imaging. 2013; 40(5):779-87.
28. Hamada K, Tomita Y, Ueda T, Enomoto K, Enomoto K, Kakunaga S, et al. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors. Annals of Nuclear Medicine. 2006; 20(10): 671-5.
29. Chen CJ, Lee BF, Yao WJ, Cheng L, Wu PS, Chu CL, et al. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. AJR Am J Roentgenol. 2008; 191(2):475-9.
30. Miyake KK, Nakamoto Y, Togashi K. Dual-time-point 18F-FDG PET/CT in patients with colorectal cancer: clinical value of early delayed scanning. Ann Nucl Med. 2012; 26 (6):492-500.
31. Rogasch JM, Steffen IG, Riedel S, Apostolova I, Wertzel H, Achenbach HJ, et al. Dual time point imaging for F18-FDG-PET/CT does not improve the accuracy of nodal staging in non-small cell lung cancer patients. Eur Radiol. 2016; 26(8):2808-18.
32. Cloran FJ, Banks KP, Song WS, Kim Y, Bradley YC. Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity. Lung Cancer. 2010; 68(1):66-71.
33. New Medicine in Japan (Monthly). 2017; 44 (3):134-9.
34. Dutour A, Decouvelaere AV, Monteil J, Duclos ME, Roualdes O, Rousseau R, et al. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemo-therapy: preclinical evaluation in an ortho-topic rat model. J Nucl Med. 2009; 50(9): 1533-40.
35. Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med. 2007; 48 (3):471-80.
36. Revheim M E, Haugvik SP, Johnsrud K, Mathisen O, Fjeld JG, Skretting A. Respiratory gated and prolonged acquisition 18F-FDG PET improve preoperative assessment of colorectal liver metastases. Acta Radiol. 2015; 56(4):397-403.
37. van der Vos CS, Arens AIJ, Hamill JJ, Hofmann C, Panin VY, Meeuwis APW, et al. Metal artifact Reduction of CT Scans to Improve
PET/CT. J Nucl Med. 2017; 58(11):1867-72.
38. Ichikawa H, Miwa K, Okuda K, Shibutani T, Kato T, Nagaki A, et al. Current state of bone scintigraphy protocols and practice in Japan. Asia Ocean J Nucl Med Biol. 2020; 8(2):116-22.